Blue Danube Systems First to Demonstrate Benefits of FDD Massive MIMO in Clustered Multi-Sector Deployments
Blue Danube Systems, a provider of intelligent wireless access solutions that help mobile operators address the challenge of explosive data growth, today announced it has successfully expanded the commercial deployment of its massive MIMO solution to multiple clustered cell sites, demonstrating total capacity improvements for directly adjoining sectors on existing LTE networks using current smartphones.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180222006158/en/
Blue Danube Systems First to Demonstrate Benefits of FDD Massive MIMO in Clustered Multi-Sector Deployments (Photo: Business Wire)
Despite the prevalent view that Massive MIMO systems will be central to 5G networks, it has not been clearly proven that the technology is deployable beyond isolated high-demand sectors where effects such as adjacent cell interference must be addressed. In fact, common digital-only Massive MIMO implementations typically operate as closed single-sector solutions, spilling unwanted Radio Frequency (RF) energy across cell edges and potentially degrading adjacent sector performance. In contrast, Blue Danube’s approach to Massive MIMO starts by assuring RF array coherency which in conjunction with digital processing uniquely enables the definition, placement and dynamic coordination of high precision beams that can be software engineered to minimize adjacent sector interference and actually improve clustered cell performance.
Using its BeamCraft™ 500 Massive MIMO systems, Blue Danube performed multi-sector beam optimization at two different sites within the FDD-LTE network at a US mobile operator. Leveraging the machine learning intelligence of the cloud-based software platform BeamPlanner™, RF patterns were generated to optimize and coordinate inter-cell and inter-sector performance. Using only two beams, improvements of 1.7 to 2.0X were demonstrated in total downlink capacity over both multi-sector locations. Additionally, critical cell edge locations saw a dramatic 7dB increase in signal quality due to BeamCraft’s precision beam control leading to 1.7X improvement in individual user download speed. Blue Danube further expects capacity improvements of 5X or more by increasing from two to four beams in future trials and will begin operation in March with a second mobile operator at a multi-sector dense urban location.
By combining precise dynamic beam control with open system interfaces, Blue Danube is engineering its Massive MIMO suite of products to interoperate with other industry network resources such as Self Optimized Network (SON), Centralized Radio Access Network (CRAN) and Open Network Application Platform (ONAP) software along with geolocation and mobile application driven analytics. Combined with BeamPlanner, these capabilities enable operators to use intelligence about their network and customer use to deliver the highest level of overall system-wide performance.
“We are excited to be the first in the industry to successfully demonstrate capacity improvement for clustered multi-sector Massive MIMO deployments,” said Mark Pinto, CEO of Blue Danube Systems. “Adding to our recent announcement of the first multi-band Massive MIMO products, we are making available powerful and flexible tools for operators to seamlessly insert 5G-ready technology into their existing LTE networks for substantial system-wide capacity gain.”
“Cell edge performance continues to be a major challenge for pure digital Massive MIMO systems,” said Shiv Panwar, Professor of Electrical Engineering at NYU and Director of the New York State Center for Advanced Technology in Telecommunications (CATT). “This is the very first demonstration of Massive MIMO performance in a clustered deployment. Blue Danube’s multi-sector BeamCraft results are very exciting and demonstrate that Massive MIMO is now viable for wide-scale adoption in FDD networks.”
“Until now, we have only seen Massive MIMO deployed on individual sectors, not on multiple sectors facing each other,” said Joe Madden, Founder and Principal Analyst at Mobile Experts. “Blue Danube’s results on clustered Massive MIMO deployments represent a critical milestone, provide compelling evidence that the technology can have broad impact across entire operator networks.”
About Blue Danube Systems
Blue Danube Systems is a privately held start-up backed by Sequoia Capital and Silver Lake along with other investors including AT&T. Blue Danube’s unique, award-winning technology combines intelligent software and hardware into a Massive MIMO solution that enables a significant increase in network capacity, utilizing existing infrastructure and today’s mobile devices. For more information, please visit www.bluedanube.com
Blue Danube Participation at Mobile World Congress 2018
Blue Danube will have representatives at Mobile World Congress from February 26 through March 1 in Barcelona. Blue Danube can be found in Hall 2, hospitality stand 2L10.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 11:00 | Pressemelding
Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines
Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 08:10 | Pressemelding
Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 15:13 | Pressemelding
Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,
Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 14:00 | Pressemelding
Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 13:41 | Pressemelding
Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 12:00 | Pressemelding
Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i